BioGX launches CE-IVD Marked COVID-19, Influenza A/B, RSV Combo RT-PCR Test for the BD MAXa?? System

AMSTERDAM, Sept. 30,A 2020 /PRNewswire/ --A BioGX BV, the European subsidiary of Birmingham, Alabama based BioGX, announced availability of a CE-IVD marked test for simultaneous detection of SARS-CoV-2, Influenza A, Influenza B and Respiratory Syncytial Virus RNA in a patient sample using the BD MAXa?? System.A  The test is offered in BioGX's trusted, easy to use Sample-Readya?? format where all required reagents for real-time PCR are lyophilized in a single tube.A  BioGX provided tube snaps into a test-specific position on the BD MAXa?? total nucleic acid extraction cartridge enabling Sample-to-Answer molecular testing.A  BioGX kits can be shipped anywhere in the world with no refrigeration required. "We are very pleased with the reliability and performance of this complex respiratory panel.A  The simultaneous detection of COVID-19, Flu A, Flu B and RSV during Flu season would help further augment the BD MAXa?? testing capacity by over 50,000 tests per week," said Shazi Iqbal, Ph.D., CEO of BioGX.A  The BioGX multiplex COVID-19, Flu A, Flu B and RSV test is intended for qualitative detection of RNA specific to SARS-CoV-2,A  Influenza A, Influenza B, and Respiratory Syncytial Virus A/B that may be present in Pharyngeal and Nasopharyngeal swab collections in transport media and saline, obtained from individuals at risk of respiratory viral infections.The BD MAXa?? System, commercialized by BD (Becton, Dickinson and Company), is a fully integrated and automated molecular diagnostic platform already in use at thousands of laboratories worldwide.A 
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2021    »